Xenco Unveils TrabeculeX Continuum, a Convergence of Digital Health and Biomaterials

Xenco Medical revealed its TrabeculeX Continuum at this year’s CES show.
 
The tool combines the U.S. Food and Drug Administration (FDA)-cleared TrabeculeX Bioactive Matrix and Recovery App to create a bridge between orthobiologics and digital health, unifying biomaterial implantation and the post-op journey. Surgeons can enroll patients in the app and engage in remote therapeutic monitoring and asynchronous video and text messaging.
 
Harnessing the hydroxycarbonate apatite-forming capabilities of bioglass, the regenerative biomaterial was engineered to conduct 3D bone formation. Its complex surface topography begins at the sub-micron scale and spans the entire lattice.
 
The Recovery App allows the doctor to prescribe and remotely monitor patient-specific physical rehab plans.
 
“As a surgical technology company devoted not only to our patients’ intraoperative care but to their longitudinal recovery, we’ve committed ourselves to dissolving the barriers that currently exist in the siloed path from surgery to rehabilitation. With the TrabeculeX Continuum, we’re excited to introduce a connective technology that recognizes the full arc of a patient’s journey rather than a single instance of care,” said Xenco Medical founder and CEO Jason Haider.